登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《CID，3月4日，2019 novel coronavirus is undergoing active recombination》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-05

  • 2019 novel coronavirus is undergoing active recombination

    Huiguang Yi

    Clinical Infectious Diseases, ciaa219, https://doi.org/10.1093/cid/ciaa219

    Published: 04 March 2020

    The 2019 novel coronavirus (2019-nCoV) outbreak in Wuhan since December 2019 [1] has quickly spread to twenty-five countries [2], caused more than 44,000 cases and 1,000 deaths sofar [3]. The fast sharing of 2019-nCoV genomes in GISAID (https://www.gisaid.org) provides a valuable dataset for 2019-nCoV haplotype network analysis, which is crucial for transmission and evolutionary track surveillance and secondary outbreak prevention.

  • 原文来源：https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa219/5781085?searchresult=1
37浏览量
原文链接
相关报告

  • 《CID，3月4日，Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-05
    • Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients Zijie Shen, Yan Xiao, Lu Kang, Wentai Ma, Leisheng Shi, Li Zhang, Zhuo Zhou, Jing Yang, Jiaxin Zhong, Donghong Yang ... Show moreAuthor Notes Clinical Infectious Diseases, ciaa203, https://doi.org/10.1093/cid/ciaa203 Published: 04 March 2020 Abstract Background A novel coronavirus (SARS-CoV-2) has infected more than 75,000 individuals and spread to over 20 countries. It is still unclear how fast the virus evolved and how the virus interacts with other microorganisms in the lung.
    28浏览量
    原文链接

  • 《CID，3月28日，Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-29
    • Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 Juanjuan Zhao, Quan Yuan, Haiyan Wang, Wei Liu, Xuejiao Liao, Yingying Su, Xin Wang, Jing Yuan, Tingdong Li, Jinxiu Li ... Show more Author Notes Clinical Infectious Diseases, ciaa344, https://doi.org/10.1093/cid/ciaa344 Published: 28 March 2020 Abstract Background The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated. Methods A total of 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2. The dynamics of antibodies with the disease progress was analyzed.
    150浏览量
    原文链接